124 related articles for article (PubMed ID: 38244911)
1. Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
Sáez-Martínez P; Porcel-Pastrana F; Montero-Hidalgo AJ; Lozano de la Haba S; Sanchez-Sanchez R; González-Serrano T; Gómez-Gómez E; Martínez-Fuentes AJ; Jiménez-Vacas JM; Gahete MD; Luque RM
Cancer Lett; 2024 Mar; 584():216604. PubMed ID: 38244911
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of the splicing machinery is directly associated to aggressiveness of prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Montero-Hidalgo AJ; Gómez-Gómez E; Fuentes-Fayos AC; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Pedraza-Arévalo S; González-Serrano T; Reyes O; Martínez-López A; Sánchez-Sánchez R; Ventura S; Yubero-Serrano EM; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
EBioMedicine; 2020 Jan; 51():102547. PubMed ID: 31902674
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin.
Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790
[TBL] [Abstract][Full Text] [Related]
4. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
5. The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D; Gahete MD; Jiménez-Vacas JM; Gómez-Gómez E; Ibáñez-Costa A; L-López F; Rivero-Cortés E; Sarmento-Cabral A; Valero-Rosa J; Carrasco-Valiente J; Sánchez-Sánchez R; Ortega-Salas R; Moreno MM; Tsomaia N; Swanson SM; Culler MD; Requena MJ; Castaño JP; Luque RM
Mol Cancer; 2017 Aug; 16(1):146. PubMed ID: 28851363
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genes.
Jiménez-Vacas JM; Montero-Hidalgo AJ; Gómez-Gómez E; Sáez-Martínez P; Fuentes-Fayos AC; Closa A; González-Serrano T; Martínez-López A; Sánchez-Sánchez R; López-Casas PP; Sarmento-Cabral A; Olmos D; Eyras E; Castaño JP; Gahete MD; Luque RM
Transl Res; 2023 Mar; 253():68-79. PubMed ID: 36089245
[TBL] [Abstract][Full Text] [Related]
7. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
8. Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3.
Fuentes-Fayos AC; Vázquez-Borrego MC; Jiménez-Vacas JM; Bejarano L; Pedraza-Arévalo S; L-López F; Blanco-Acevedo C; Sánchez-Sánchez R; Reyes O; Ventura S; Solivera J; Breunig JJ; Blasco MA; Gahete MD; Castaño JP; Luque RM
Brain; 2020 Dec; 143(11):3273-3293. PubMed ID: 33141183
[TBL] [Abstract][Full Text] [Related]
9. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1.
Beaulieu YB; Kleinman CL; Landry-Voyer AM; Majewski J; Bachand F
PLoS Genet; 2012; 8(11):e1003078. PubMed ID: 23166521
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of the long non-coding RNA FALEC promotes proliferation and migration of prostate cancer cell lines and predicts prognosis of PCa patients.
Zhao R; Sun F; Bei X; Wang X; Zhu Y; Jiang C; Zhao F; Han B; Xia S
Prostate; 2017 Jul; 77(10):1107-1117. PubMed ID: 28585762
[TBL] [Abstract][Full Text] [Related]
11. Unleashing the Diagnostic, Prognostic and Therapeutic Potential of the Neuronostatin/GPR107 System in Prostate Cancer.
Sáez-Martínez P; Jiménez-Vacas JM; León-González AJ; Herrero-Aguayo V; Montero Hidalgo AJ; Gómez-Gómez E; Sánchez-Sánchez R; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32498336
[TBL] [Abstract][Full Text] [Related]
12. Micro-RNA-186-5p inhibition attenuates proliferation, anchorage independent growth and invasion in metastatic prostate cancer cells.
Jones DZ; Schmidt ML; Suman S; Hobbing KR; Barve SS; Gobejishvili L; Brock G; Klinge CM; Rai SN; Park J; Clark GJ; Agarwal R; Kidd LR
BMC Cancer; 2018 Apr; 18(1):421. PubMed ID: 29653561
[TBL] [Abstract][Full Text] [Related]
13. Snail-activated long non-coding RNA PCA3 up-regulates PRKD3 expression by miR-1261 sponging, thereby promotes invasion and migration of prostate cancer cells.
He JH; Li BX; Han ZP; Zou MX; Wang L; Lv YB; Zhou JB; Cao MR; Li YG; Zhang JZ
Tumour Biol; 2016 Oct; ():. PubMed ID: 27743381
[TBL] [Abstract][Full Text] [Related]
14. LncFALEC recruits ART5/PARP1 and promotes castration-resistant prostate cancer through enhancing PARP1-meditated self PARylation.
Shi F; Wu L; Cui D; Sun M; Shen Y; Zhou Z; Deng Z; Han B; Xia S; Zhu Z; Sun F
Cell Oncol (Dordr); 2023 Jun; 46(3):761-776. PubMed ID: 36913068
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer.
Pedraza-Arévalo S; Hormaechea-Agulla D; Gómez-Gómez E; Requena MJ; Selth LA; Gahete MD; Castaño JP; Luque RM
Prostate; 2017 Nov; 77(15):1499-1511. PubMed ID: 28905400
[TBL] [Abstract][Full Text] [Related]
16. The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA.
Shi X; Zhang W; Nian X; Lu X; Li Y; Liu F; Wang F; He B; Zhao L; Zhu Y; Ren S; Sun Y
Int J Cancer; 2020 Jan; 146(2):475-486. PubMed ID: 31107971
[TBL] [Abstract][Full Text] [Related]
17. Spliceosomal profiling identifies EIF4A3 as a novel oncogene in hepatocellular carcinoma acting through the modulation of FGFR4 splicing.
López-Cánovas JL; Hermán-Sánchez N; Moreno-Montilla MT; Del Rio-Moreno M; Alors-Perez E; Sánchez-Frias ME; Amado V; Ciria R; Briceño J; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Clin Transl Med; 2022 Nov; 12(11):e1102. PubMed ID: 36419260
[TBL] [Abstract][Full Text] [Related]
18. PABPN1 functions as a predictive biomarker in colorectal carcinoma.
Wang QH; Yan PC; Shi LZ; Teng YJ; Gao XJ; Yao LQ; Liang ZW; Zhou MH; Han W; Li R
Mol Biol Rep; 2023 Dec; 51(1):40. PubMed ID: 38158471
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of the miRNome unveils a crosstalk between obesity and prostate cancer: miR-107 asa personalized diagnostic and therapeutic tool.
Herrero-Aguayo V; Sáez-Martínez P; Jiménez-Vacas JM; Moreno-Montilla MT; Montero-Hidalgo AJ; Pérez-Gómez JM; López-Canovas JL; Porcel-Pastrana F; Carrasco-Valiente J; Anglada FJ; Gómez-Gómez E; Yubero-Serrano EM; Ibañez-Costa A; Herrera-Martínez AD; Sarmento-Cabral A; Gahete MD; Luque RM
Mol Ther Nucleic Acids; 2022 Mar; 27():1164-1178. PubMed ID: 35282415
[TBL] [Abstract][Full Text] [Related]
20. Propofol suppresses colorectal cancer development by the circ-PABPN1/miR-638/SRSF1 axis.
Zhao A; Liu Y
Anal Biochem; 2021 Oct; 631():114354. PubMed ID: 34453920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
